|
|
Vaccine Detail
|
pNGVL3-hICD Vaccine |
| Vaccine Information |
- Vaccine Name: pNGVL3-hICD Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007011
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: ERBB2
- ERBB2
gene engineering:
- Description: This is for Breast Cancer (NCT05163223). A plasmid DNA cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene. Upon administration and after cellular uptake by skin or muscle cells, the pNGVL3-hICD vaccine plasmid expresses the HER-2/neu protein, which, after intracellular processing, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance. (NCIT_C61146).
|
| Host Response |
|
|
| References |
Griguolo et al., 2019: Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. Journal for immunotherapy of cancer. 2019; 7(1); 90. [PubMed: 30922362].
NCIT_C61146: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61146]
NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (Cornerstone001) [https://clinicaltrials.gov/ct2/show/NCT05163223]
|
|
